マーケットレポート詳細

インスリン製剤および送達技術：世界市場2027年予測

Global Markets for Insulin Drug and Delivery Technologies

出版元：BCC Research 　 出版元について
発行年：2022年8月
定価 Single User License(1名様ライセンス)US$5,500 (米国ドル) /2 to 5 Users License(5名様)$6,600 /Site License $7,920 / Enterprise License $9,504
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算（お見積り日TTSレート）となります。
納品形態：PDF by Email
当調査レポートは英文120ページになります。
商品コード：BCC425

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。

【レポート紹介】

インスリン製剤および送達技術の世界市場規模2022年で558億ドル、2027年に889億ドル、市場の平均年成長率は9.8%になると推測されます。
当レポートでは、市場ダイナミクス、市場概要、規制動向/償還シナリオ、COVID-19の影響、市場概要、各種セグメント別市場分析(デバイスタイプ別、インスリンタイプ別、国地域別)、市場機会分析、競合状況、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】

◆イントロダクション

・調査目的                                                                                                        
・調査対象
・調査手法

◆サマリーと調査ハイライト

◆市場ダイナミクス

・ドライバー
・障壁
・機会

◆市場概要

・市場動向
・現在の市場トレンド
・将来の展望

◆規制動向/償還シナリオ

・規制動向
・償還シナリオ
・保険

◆COVID-19の影響

・概要
・COVID-19危機

◆デバイスタイプ別市場

インスリン送達技術
・シリンジ
・インスリンペン
・インスリンポンプ
・スマートインスリンペン
・その他
※市場予測データ掲載-2027年

◆インスリンタイプ別市場

・持効型インスリン
・超速効型インスリン
・中間型インスリン
・短時間作用型インスリン
・混合型インスリン
※市場予測データ掲載-2027年

◆地域別市場

北米
欧州
アジア太平洋
その他地域
※地域別に全セグメントの細分化データ掲載
※地域別に主要国別の細分化データ掲載

◆市場機会分析

ファイブフォース分析

◆競合状況

◆インスリン製剤および送達技術の主要企業プロフィール

B. BRAUN MELSUNGEN AG
BECTON, DICKINSON AND CO.
BIOCON
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
MEDTRONIC INC.
NOVO NORDISK A/S
SANOFI
VIATRIS INC.
YPSOMED HOLDING AG

(その他企業)
CEQUR SIMPLICITY
DEBIOTECH SA
EMPERRA GMBH E-HEALTH TECHNOLOGIES
INSULET CORP.
NANOPASS TECHNOLOGIES LTD.
NIPRO MEDICAL CORP.
OWEN MUMFORD LTD.
TANDEM DIABETES CARE INC.
（全120頁）


【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

Table of Contents (英文詳細目次）

Chapter 1 Introduction

1.1 Insulin Overview
1.2 Diabetes Overview

  • 1.2.1 Disease Symptoms and Risk Factors
  • 1.2.2 Epidemiology and Economic Burden

1.3 Study Goals and Objectives
1.4 Reasons for Doing this Study
1.5 What's New in this Update?
1.6 Scope of Report
1.7 Information Sources
1.8 Methodology
1.9 Geographic Breakdown
1.10 Analyst's Credentials
1.11 BCC Custom Research
1.12 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics

3.1 Market Drivers

  • 3.1.1 Rising Prevalence of Diabetes
  • 3.1.2 Smart Insulin Drug Delivery Technologies
  • 3.1.3 Painless Insulin Drug Delivery Technologies

3.2 Market Restraints

  • 3.2.1 Product Recalls

3.3 Market Opportunities

  • 3.3.1 Inorganic Strategies amongst Market Players

Chapter 4 Market Overview

4.1 Market Insights

  • 4.1.1 Insulin
  • 4.1.2 Diabetes

4.2 Current Market Trends

  • 4.2.1 Recent Product Introductions
  • 4.2.2 Recent Strategic Alliances

4.3 Future Perspective

Chapter 5 Regulatory Landscape and Reimbursement Scenario

5.1 Regulatory Landscape

  • 5.1.1 U.S. Regulations for Medical Devices
  • 5.1.2 U.S. Drug Regulations
  • 5.1.3 European Regulations for Medical Devices
  • 5.1.4 European Regulations for Drugs
  • 5.1.5 Asia-Pacific Regulations for Medical Devices

5.2 Reimbursement Scenario

  • 5.2.1 Pricing and Reimbursement Overview
  • 5.2.2 Pricing and Reimbursement for Medical Devices
  • 5.2.3 Pricing and Reimbursement for Pharmaceuticals

5.3 Insurance

  • 5.3.1 Insurance for Diabetic Emergencies

Chapter 6 Impact of COVID-19 on Market

6.1 Overview
6.2 COVID-19 Crisis

  • 6.2.1 Impact on Market for Insulin Drug and Delivery Technologies
  • 6.2.2 COVID-19 Measures

Chapter 7 Market Breakdown by Device Type

7.1 Insulin Delivery Technologies

  • 7.1.1 Syringes
  • 7.1.2 Insulin Pens
  • 7.1.3 Insulin Pumps
  • 7.1.4 Smart Pens
  • 7.1.5 Others

Chapter 8 Market Breakdown by Insulin Type

8.1 Insulin

  • 8.1.1 Structure of Insulin
  • 8.1.2 Insulin Biosynthesis
  • 8.1.3 Insulin Types

Chapter 9 Market Breakdown by Region

9.1 Overview

  • 9.1.1 North America
  • 9.1.2 Europe
  • 9.1.3 Asia-Pacific
  • 9.1.4 Rest of the World

Chapter 10 Analysis of Market Opportunities

10.1 Porter's Five Forces Analysis

  • 10.1.1 Threat of New Entrants
  • 10.1.2 Threat of Substitutes
  • 10.1.3 Bargaining Power of Suppliers
  • 10.1.4 Bargaining Power of Buyers
  • 10.1.5 Degree of Competition

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

12.1 Major Companies
B. BRAUN MELSUNGEN AG
BECTON, DICKINSON AND CO.
BIOCON
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
MEDTRONIC INC.
NOVO NORDISK A/S
SANOFI
VIATRIS INC.
YPSOMED HOLDING AG
Other Companies
CEQUR SIMPLICITY
DEBIOTECH SA
EMPERRA GMBH E-HEALTH TECHNOLOGIES
INSULET CORP.
NANOPASS TECHNOLOGIES LTD.
NIPRO MEDICAL CORP.
OWEN MUMFORD LTD.
TANDEM DIABETES CARE INC.

Chapter 13 Appendix: Acronyms

List of Tables

Summary Table : Global Market for Insulin Drug and Delivery Technologies, by Device Type, Through 2027
Table 1 : Cases of Diabetes Worldwide, by Type
Table 2 : Global Prevalence of Diabetes, by Type, Through 2040
Table 3 : Global Diabetes Estimates and Projections, 2019–2045
Table 4 : History of Insulin Isolation and Development
Table 5 : Currently Available Insulin Brands
Table 6 : Features of Type 1 and Type 2 Diabetes
Table 7 : Strategic Alliances in the Market for Insulin Drug and Delivery Technologies, 2020-2022
Table 8 : Insulin Drug and Delivery Technologies Pipeline
Table 9 : Global Market for Insulin Drug and Delivery Technologies, by Device Type, Through 2027
Table 10 : Advantages and Disadvantages of Syringes
Table 11 : Global Market for Syringe Delivery Technologies, by Region, Through 2027
Table 12 : Advantages and Disadvantages of Insulin Pens
Table 13 : Global Market for Insulin Pen Delivery Technologies, by Region, Through 2027
Table 14 : Advantages and Disadvantages of Insulin Pumps
Table 15 : Global Market for Insulin Pump Delivery Technologies, by Region, Through 2027
Table 16 : Global Market for Smart Insulin Pen Delivery Technologies, by Region, Through 2027
Table 17 : Global Market for Other Types of Delivery Technologies, by Region, Through 2027
Table 18 : Advantages and Disadvantages of Various Insulin Delivery Systems
Table 19 : Types of Insulin and Their Features
Table 20 : Global Market for Insulin Drug and Delivery Technologies, by Insulin Type, Through 2027
Table 21 : Global Market for Long-acting Insulin, by Region, Through 2027
Table 22 : Global Market for Rapid-acting Insulin, by Region, Through 2027
Table 23 : Global Market for Intermediate-acting Insulin, by Region, Through 2027
Table 24 : Global Market for Short-acting Insulin, by Region, Through 2027
Table 25 : Global Market for Premixed Insulin, by Region, Through 2027
Table 26 : Global Market for Insulin Drug and Delivery Technologies, by Region, Through 2027
Table 27 : Diabetes Estimates in North America, by Country, 2000–2045
Table 28 : North American Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
Table 29 : Diabetes Estimates in Europe, by Country, 2000–2045
Table 30 : European Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
Table 31 : Diabetes Estimates for the Asia-Pacific Region, by Country, 2000–2045
Table 32 : Asia-Pacific Market for Insulin Drug and Delivery Technologies, by Country, Through 2027
Table 33 : Diabetes Estimates in the RoW, by Country, 2000–2045
Table 34 : Porter's Five Forces Analysis: Insulin Drug and Delivery Technologies Market
Table 35 : B. Braun Melsungen: Insulin Drug and Delivery Product Portfolio
Table 36 : BD: Insulin Drug and Delivery Product Portfolio
Table 37 : Biocon: Insulin Product Portfolio
Table 38 : Biocon: Key Developments, 2020-2021
Table 39 : Boehringer Ingelheim: Insulin Product Portfolio
Table 40 : Eli Lilly: Insulin Products
Table 41 : Eli Lilly: Key Developments, 2020-2021
Table 42 : F. Hoffmann-La Roche: Insulin Drug and Delivery Product Portfolio
Table 43 : F. Hoffmann-La Roche: Key Developments, 2021
Table 44 : Medtronic: Insulin Drug and Delivery Products Portfolio
Table 45 : Medtronic: Key Developments, 2020-2021
Table 46 : Novo Nordisk: Insulin Drug and Delivery Products Portfolio
Table 47 : Novo Nordisk: Key Developments, 2018-2022
Table 48 : Sanofi: Insulin Drug and Delivery Products Portfolio
Table 49 : Sanofi: Key Developments, 2018-2021
Table 50 : Viatris: Insulin Drug and Delivery Products Portfolio
Table 51 : Viatris: Key Developments, 2021
Table 52 : Ypsomed Holding AG: Insulin Drug and Delivery Products Portfolio
Table 53 : Ypsomed Holding AG: Key Developments, 2020-2022
Table 54 : Acronyms Used in This Report

List of Figures

Figure A : Timeline of Major Insulin Breakthroughs
Summary Figure A : Global Insulin Drug and Delivery Technologies Market
Summary Figure B : Global Market Shares of Insulin Drug and Delivery Technologies, by Device Type, 2021
Figure 1 : Cases of Diabetes Worldwide, by Type
Figure 2 : Global Prevalence of Diabetes, by Type, 2018–2040
Figure 3 : Medical Device Marketing Process in the U.S.
Figure 4 : Global Market Shares of Insulin Delivery Technologies, 2021 and 2027
Figure 5 : Global Market for Syringes Delivery Technologies, 2020-2027
Figure 6 : Global Market for Insulin Pen Delivery Technologies, 2020-2027
Figure 7 : Global Market for Insulin Pump Delivery Technologies, 2020-2027
Figure 8 : Global Market for Smart Insulin Pen Delivery Technologies, 2020-2027
Figure 9 : Global Market for Other Types of Delivery Technologies, 2020-2027
Figure 10 : Global Market Shares of Insulin Drug and Delivery Technologies, by Insulin Type, 2021 and 2027
Figure 11 : Global Market for Long-acting Insulin, 2020-2027
Figure 12 : Global Market for Rapid-acting Insulin, 2020-2027
Figure 13 : Global Market for Intermediate-acting Insulin, 2021-2027
Figure 14 : Global Market for Short-acting Insulin, 2020-2027
Figure 15 : Global Market for Premixed Insulin, 2020-2027
Figure 16 : Snapshot of Global Market for Insulin Drug and Delivery Technologies, 2021
Figure 17 : Global Market Shares of Insulin Drug and Delivery Technologies, by Region, 2021
Figure 18 : Snapshot of North American Market for Insulin Drug and Delivery Technologies, 2021
Figure 19 : North American Market for Insulin Drug and Delivery Technologies, by Country, 2021-2027
Figure 20 : Snapshot of European Market for Insulin Drug and Delivery Technologies, 2021
Figure 21 : European Market for Insulin Drug and Delivery Technologies, by Country, 2020-2027
Figure 22 : European Market Shares of Insulin Drug and Delivery Technologies, by Country, 2021
Figure 23 : Snapshot of Asia-Pacific Market for Insulin Drug and Delivery Technologies, 2021
Figure 24 : Asia-Pacific Market for Insulin Drug and Delivery Technologies, by Country, 2021-2027
Figure 25 : Asia-Pacific Market Shares of Insulin Drug and Delivery Technologies, by Country, 2021
Figure 26 : Global Market Shares of Insulin Drug and Delivery Technologies, by Company, 2021
Figure 27 : B. Braun Melsungen: Annual Revenue, 2018-2021
Figure 28 : B. Braun Melsungen: Revenue Share, by Division, 2021
Figure 29 : BD: Annual Revenue, 2018-2021
Figure 30 : BD: Revenue Share, by Business Segment, 2021
Figure 31 : Boehringer Ingelheim: Annual Revenue, 2018-2021
Figure 32 : Boehringer Ingelheim: Revenue Share, by Business Segment, 2021
Figure 33 : Eli Lilly: Annual Revenue, 2018-2021
Figure 34 : F. Hoffmann-La Roche: Annual Revenue, 2018-2021
Figure 35 : F. Hoffmann-La Roche: Revenue Share, by Division, 2021
Figure 36 : Medtronic: Annual Revenue, 2018-2021
Figure 37 : Medtronic: Revenue Share, by Business Segment, 2021
Figure 38 : Novo Nordisk: Annual Revenue, 2018-2021
Figure 39 : Novo Nordisk: Revenue Share, by Business Segment, 2021
Figure 40 : Sanofi: Annual Revenue, 2018-2021
Figure 41 : Sanofi: Revenue Share, by Business Unit, 2021
Figure 42 : Viatris: Annual Revenue, 2018-2021
Figure 43 : Viatris: Revenue Share, by Product Category, 2020
Figure 44 : Ypsomed Holding AG: Annual Revenue, 2018-2021
Figure 45 : Ypsomed Holding AG: Revenue Share, by Business Unit, 2021


△ 一番上に戻る